Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn’s Disease Treated With Anti-TNF-α Biologics
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad181 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Giorgio Guglielmi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Biological Products, Crohn Disease, MicroRNAs. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: University of Pisa.
Abstract (Originalsprache)
Background
The identification of new biomarkers predictive of response to antitumor necrosis factor alpha (anti-TNF-α) monoclonal antibodies remains an unmet medical need in Crohn’s disease (CD) because a high percentage of patients show no clinical improvement after treatment or can lose response over time. MicroRNAs (miRNAs) can regulate inflammatory and immunological responses and were found to play a role in CD.
Methods
Baseline serum samples from 37 CD patients previously treated with infliximab or adalimumab, as per clinical practice, were obtained from the serum library at the Gastroenterology Unit of the University Hospital of Pisa, Italy. Patients were categorized as responders or nonresponders based on the following treatment outcomes: clinical remission at weeks 14 and 54 and endoscopic remission at week 54. The expression levels of a panel of selected miRNAs were analyzed by real-time polymerase chain reaction. Comparisons of miRNA expression between responders and nonresponders and statistical analyses were performed by MedCalc and GraphPad Prism software. Receiver operating characteristic curve analyses were calculated to evaluate the predictive performance of potential biomarkers.
Results
Patients in clinical remission at week 14 had a lower let-7e expression, whereas those in clinical remission at week 54 had lower levels of circulating miR-126 than nonresponders. The receiver operating characteristic curve analysis identified optimal cutoff values with assay sensitivity and specificity of 92.9% and 61.1%, for let-7e, and 62.5% and 83.3%, for miR-126, respectively.
Conclusion
These results provide evidence that expression levels of circulating let-7e and miR-126 at baseline may predict clinical remission in CD patients treated with anti-TNF-α biologics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- IBD Unit, Department of General Surgery and Gastroenterology, University Hospital of Pisa, Pisa, Italy.
ORCID-Profile: Lorenzo Bertani, Romano Danesi, Stefano Fogli
Förderung
- University of Pisa
Zitieren
APA
Guglielmi, G., Crucitta, S., Bertani, L., Ruglioni, M., Baiano Svizzero, G., Ceccarelli, L., Del Re, M., Danesi, R., Costa, F., & Fogli, S. (2024). Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn’s Disease Treated With Anti-TNF-α Biologics. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad181
Vancouver
Guglielmi G, Crucitta S, Bertani L, Ruglioni M, Baiano Svizzero G, Ceccarelli L, et al. Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn’s Disease Treated With Anti-TNF-α Biologics. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad181
BibTeX
@article{Guglielmi2024,
author = {Guglielmi, Giorgio and Crucitta, Stefania and Bertani, Lorenzo and Ruglioni, Martina and Baiano Svizzero, Giovanni and Ceccarelli, Linda and Del Re, Marzia and Danesi, Romano and Costa, Francesco and Fogli, Stefano},
title = {Expression of Circulating let-7e and miR-126 May Predict Clinical Remission in Patients With Crohn’s Disease Treated With Anti-TNF-α Biologics},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad181}
}
EUVIMED